PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fezolinetant. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

36 hits

Bibliografisk träff 2024-04-02

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.

Akhtar SMM, Ali A, Khan MS, Khan V, Fareed A, Saleem SZ, Mumtaz M, Ahsan MN, Iqbal S, Asghar MS.

Int J Gynaecol Obstet · meta-analysis; systematic review; journal article · DOI 10.1002/ijgo.15467

Bibliografisk träff 2024-04-01

Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.

Reed SD.

Menopause · journal article · DOI 10.1097/gme.0000000000002346

Bibliografisk träff 2024-04-01

Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).

Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD.

Menopause · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1097/gme.0000000000002340

Bibliografisk träff 2024-03-13

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.

Rani P, Zehra D, Mansoor M, Rani P.

Arch Womens Ment Health · journal article · DOI 10.1007/s00737-024-01456-y

Bibliografisk träff 2024-03-11

Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.

Cieri-Hutcherson NE, Marji EK, Hutcherson TC.

Menopause · systematic review; journal article · DOI 10.1097/gme.0000000000002328

Bibliografisk träff 2024-03-01

Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.

Crespo C, Erlich D.

Am Fam Physician · journal article

Bibliografisk träff 2024-03-01

Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.

Elhusein AM, Fadlalmola HA, Abedelwahed HH, Elshaikh AA, Banaga AE, Alrahman MHF, Abdelgadim NH, Mohammed IH, Abdalla AAA, Abdalla FAM, Abd Allah EM, Abbas NI, Alhujaili AD, Almkiy EA, Idress EA, Awadalkareem EM, Abdeldafie SY, Balusamy P, Mohamed RA, Aloufi RSM, Habiballa M, Abdelmalik MA, Alhejaili MM, Ibrahim IA, Masaad HK.

Afr J Reprod Health · meta-analysis; systematic review; journal article · DOI 10.29063/ajrh2024/v28i3.11

Bibliografisk träff 2024-02-06

Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.

Cano A, Nappi RE, Santoro N, Stute P, Blogg M, English ML, Morga A, Scrine L, Siddiqui E, Ottery FD.

BJOG · randomized controlled trial; journal article · DOI 10.1111/1471-0528.17773

Bibliografisk träff 2024-01-16

Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.

Bonga KN, Mishra A, Maiti R, Padhy BM, Meher BR, Srinivasan A.

Obstet Gynecol · meta-analysis; journal article · DOI 10.1097/aog.0000000000005508

Bibliografisk träff 2024-01-01

[Endocrinology: what's new in 2023].

Ameti A, Chouchane K, Fontana E, Papadakis GE.

Rev Med Suisse · review; journal article; english abstract · DOI 10.53738/revmed.2024.20.856-7.36

Bibliografisk träff 2023-12-28

A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.

Javernick JA.

Nurs Womens Health · journal article · DOI 10.1016/j.nwh.2023.11.005

Bibliografisk träff 2023-12-01

Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.

Rahman UA, Kashif TB, Usman M, Rana M, Hasanain M, Anjum MU, Cheema HA, Jaffar H, Bhattarai P.

Medicine (Baltimore) · meta-analysis; research-article; systematic review; journal article · DOI 10.1097/md.0000000000036592

Bibliografisk träff 2023-11-27

Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R.

Menopause · research-article; systematic review; network meta-analysis; journal article · DOI 10.1097/gme.0000000000002281

Bibliografisk träff 2023-10-18

Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.

Douxfils J, Beaudart C, Dogné JM.

Lancet · letter · DOI 10.1016/s0140-6736(23)01634-3

Bibliografisk träff 2023-10-10

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.

Langley PC.

Innov Pharm · discussion; journal article · DOI 10.24926/iip.v14i1.5118

Bibliografisk träff 2023-10-05

"Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".

Shaukat A, Mujeeb A, Shahnoor S, Nasser N, Khan AM.

Health Sci Rep · letter; journal article · DOI 10.1002/hsr2.1610

Bibliografisk träff 2023-10-01

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.

Pinkerton JV, Redick DL, Homewood LN, Kaunitz AM.

J Clin Endocrinol Metab · article-commentary; comment; editorial · DOI 10.1210/clinem/dgad209

Bibliografisk träff 2023-09-16

Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.

Onge ES, Phillips B, Miller L.

J Pharm Technol · review-article; review; journal article · DOI 10.1177/87551225231198700

Bibliografisk träff 2023-08-01

Fezolinetant.

Författaruppgift saknas

Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad125

Bibliografisk träff 2023-08-01

Fezolinetant: First Approval.

Lee A.

Drugs · review; journal article · DOI 10.1007/s40265-023-01917-1

Bibliografisk träff 2023-08-01

Neurokinin 3 receptor antagonism for menopausal hot flashes.

Comninos AN, Dhillo WS.

Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/j.cell.2023.07.011

Bibliografisk träff 2023-07-11

Fezolinetant.

Beninger P.

Clin Ther · editorial · DOI 10.1016/j.clinthera.2023.06.019

Bibliografisk träff 2023-07-07

Fezolinetant for menopausal hot flashes and night sweats.

González-García I, López M.

Trends Pharmacol Sci · journal article · DOI 10.1016/j.tips.2023.06.003

Bibliografisk träff 2023-07-01

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N.

J Clin Endocrinol Metab · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1210/clinem/dgad058

Bibliografisk träff 2023-06-15

Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.

DePree B.

touchREV Endocrinol · review-article; review; journal article · DOI 10.17925/ee.2023.19.2.13

Bibliografisk träff 2023-06-01

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.

Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD.

J Manag Care Spec Pharm · brief-report; journal article · DOI 10.18553/jmcp.2023.29.6.692

Bibliografisk träff 2023-06-01

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.

Hassan F, Saleem A, Samuel SS, Sarfraz Z, Sarfraz A, Sarfraz M, Kc M.

Medicine (Baltimore) · research-article; systematic review; journal article · DOI 10.1097/md.0000000000033978

Bibliografisk träff 2023-06-01

Fezolinetant (Veozah) for menopausal vasomotor symptoms.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1679a

Bibliografisk träff 2023-06-01

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.

Gompel A, Stuenkel CA.

Cell Rep Med · news; journal article · DOI 10.1016/j.xcrm.2023.101076

Bibliografisk träff 2023-03-13

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G.

Lancet · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)00085-5